Genentech granted FDA hearing on Avastin for metastatic breast cancer

[News]

Genentech, a member of the Roche Group, today announced the U.S. Food and Drug Administration (FDA) has granted a hearing to allow the company the opportunity to present its views on why Avastin® (bevacizumab) should remain FDA-approved for metastatic breast cancer (mBC). The FDA has scheduled the hearing for June 28 to 29, 2011.

More... (http://www.news-medical.net/news/20110225/Genentech-granted-FDA-hearing-on-Avastin-for-metastatic-breast-cancer.aspx)